SLNO Q1 2017 Earnings — Soleno Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

SLNOSoleno Therapeutics, Inc.

$2B

Q1 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$265,000-40.7% YoY

Gross Profit

$56,00021.1% margin

Operating Income

-$2M-834.0% margin

Net Income

-$3M-1089.4% margin

EPS (Diluted)

$-8.51

QoQ Revenue Growth

-6.6%

Cash Flow

Operating Cash Flow

-$2M

Free Cash Flow

-$2M

Stock-Based Comp.

$185,000

Balance Sheet

Total Assets

$34M

Total Liabilities

$4M

Stockholders' Equity

$30M

Cash & Equivalents

$11M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$265,000	$447,000	-40.7%
Gross Profit	$56,000	-$14,000	+500.0%
Operating Income	-$2M	-$4M	+48.2%
Net Income	-$3M	-$3M	+9.5%